IP Library › Granted Patent US 12,691,078
Granted Patent B2
US 12,691,078 · App. 17/945,010 · Granted Jul 28, 2026

Stable compositions of functional ingredients and methods of making the same

Inventor: Ehsan Moaseri (Austin, TX)
Assignee: Nulixir Inc.
A61K9/51A61K31/13A61K31/137A61K31/165A61K31/343A61K31/4025A61K31/4458A61K31/465A61K31/522A61K31/60A61K31/658A61K36/07A61K36/16A61K36/23A61K36/258A61K36/28A61K36/37A61K36/481A61K36/53A61K36/54A61K36/67A61K36/88A61K36/9068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,691,078
App. No.
17/945,010
Filed
Sep 14, 2022
Granted
Jul 28, 2026
Kind
B2
Art Unit
1617
USPC
424/499
Abstract

Provided is a composition, including: an aqueous suspension, comprising: a first plurality of active ingredients, and one or more nanoparticles, wherein: the one or more nanoparticles encapsulate a second plurality of active ingredients; the second plurality of active ingredients are insoluble in the aqueous suspension; the one or more nanoparticles solubilize the second plurality of active ingredients in the aqueous suspension; and the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers.

Claims (55)

1 . A composition for oral consumption, comprising:

an aqueous suspension, comprising:

a first plurality of active ingredients, wherein:

the first plurality of active ingredients are soluble in the aqueous suspension; and

one or more nanoparticles, wherein:

the one or more nanoparticles encapsulate a second plurality of active ingredients;

the second plurality of active ingredients are insoluble in the aqueous suspension;

the one or more nanoparticles solubilize the second plurality of active ingredients in the aqueous suspension;

the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers;

the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 40° C. for four weeks;

the one or more nanoparticles has a charge that is larger than 15 mV;

the one or more nanoparticles comprise a crosslinked hydrophilic polymer network at an interface of the one or more nanoparticles; and

the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 90° C. for 30 minutes.

2 . The composition of claim 1 , wherein:

the second plurality of active ingredients is selected from the group consisting of Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna , black truffle, Syzygium aromaticum, Rosmarinus oficinalis, Sceletium tortuosum , Holy basil, Oregano, Lavender, Cinnamon, Malabathrum, Cananga odorata, Ginkgo biloba, Bacopa , and Rhodiola rosea , Ashwagandha, Astragalus, Chaga, Cordyceps, Corydalis , Curcumin, Damiana, Eleuthero, Ginger root, Ginseng , Gotu Kola, Lion's Mane, Maca, Passionflower, Saffron, Schisandra, St. John's Wort, Turmeric, Turkey Tail, Valerian root, Yohimbe, or combinations thereof.

3 . The composition of claim 1 , wherein:

the second plurality of active ingredients is selected from the group consisting of cannabidiol, cannabichromene, cannabigerol, cannabicyclol, cannabinol, cannabigerolic acid, cannabigerolic acid monomethylether, cannabigerol monomethyl ether, cannabichromanon, cannabichromenic acid, cannabichromevarin, cannabichromevarinic acid, tetrahydrocannabinol, iso-tetrahydrocannabinol, cannabinol methylether, cannabinol-C4, cannabinol-C2, cannabiorcol, cannabinodiol, cannabielsoin, cannabielsoic acid A, cannabielsoic acid B, cannabicyclol, cannabicyclolic acid, cannabicyclovarin, cannabicitran, cannabitriol, cannabitriolvarin, ethoxy-cannabitiolvarin, cannabivarin, cannabinodivarin, tetrahydrocannabivarin, cannabidivarin, cannabigerovarin, cannabigerovarinic acid, cannabifuran, dehydrocannabifuran, cannabiripsol cannabinoids, or combinations thereof.

4 . The composition of claim 1 , wherein the composition is a beverage, a gum, or a food snack.

5 . The composition of claim 1 , wherein the one or more nanoparticles further comprising:

a plurality of emulsifying agents selected from the group consisting of an extract of Quillaja, extract of Licorice, polysorbate 20, polysorbate 40, polysorbate 45, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81 and polysorbate 85, polyglyceryl, gum acacia, Polyglycerol polyricinoleate, sorbitan 85, sorbitan 65, sorbitan 83, sorbitan 80, sorbitan 60, sorbitan 40, Xanthan gum, sorbitol, mannitol, glycerol, sodium alginate, lecithin, chemically modified lecithin, purified components of lecithin, phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, and cardiolipin, hydrogenated soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, tocopherol polyethylene glycol succinate, fatty acid mono-and di-glycerides, acetic acid esters of mono-and di-glycerides, lactic acid esters of mono-and di-glycerides, citric acid esters of mono-and di-glycerides, diacetyl tartaric acid ester of mono-and di-glycerides, triglycerol monooleate, hexaglycerol octasterate, polyglycerol esters of oleic acid, decaglycerol mono-and di-oleate, glyceryl caprylate, glyceryl caprate, glyceryl caprate/caprylate, glyceryl monooleate, glycerly monostearate, poloxamers, milk proteins, casein, pea proteins, whey proteins, collagen, sodium stearoyl lactylate, extract of bacopa, withaferin A, withaferin B, withanolide A, withanolide B, withanolide C, withanolide D, withanolide E, withanolide F, withanolide G, withanoside I, withanoside II, withanoside III, withanoside IV, withanoside V, withanoside VI, withanoside VII, bacopaside I, bacopaside II, bacopaside III, bacopaside IV, bacopaside V, bacopaside VI, bacopaside VII, bacopaside VIII, bacopaside IX, bacopaside X, bacopaside XI, bacopaside XII, bacopaside N1, bacopaside N2, bacosaponin A, bacosaponin B, bacosaponin C, bacosaponin D, bacosaponin E, bacosaponin F, bacosaponin G, bacosaponin H, bacoside A3, bacosine, or combinations thereof.

6 . The composition of claim 1 , wherein the aqueous suspension further comprising:

a first polymer selected from the group consisting of alginic acid, gum Arabic, locust bean gum, sodium alginate, potassium alginate, calcium alginate, agar, guar gum, and xanthan gum.

7 . The composition of claim 1 , wherein the one or more nanoparticles further comprising:

a dispersed phase comprising:

a third plurality of active ingredients; and

a second polymer.

8 . The composition of claim 7 , wherein:

the third plurality of active ingredients is selected from the group consisting of methylphenidate, dextroamphetamine, amphetamine, Caffeine, nicotine, Methamphetamine, 3,4-Methylenedioxymethamphetamine, Methylenedioxypyrovalerone, Mephedrone, Phenylpropanolamine, Propylhexedrine, Pseudoephedrine, Catha edulis , Modafinil, xanthines, theophylline, and theobromine, or combinations thereof.

9 . The composition of claim 7 , wherein:

the second polymer is selected from the group consisting of alginic acid, gum Arabic, locust bean gum, sodium alginate, potassium alginate, calcium alginate, agar, guar gum, and xanthan gum.

10 . The composition of claim 1 , wherein the one or more nanoparticles further comprising:

a first polymer selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, shellac, ethyl methyl cellulose, carboxymethyl cellulose, ethyl cellulose, microcrystalline cellulose, cellulose, 12-hydroxystearic acid, and a combination thereof.

11 . The composition of claim 10 , wherein the first polymer retards the release of the second plurality of active ingredients after consumption.

12 . The composition of claim 1 , wherein the one or more nanoparticles has a net negative charge that is −15 mV or lower.

13 . The composition of claim 12 , wherein the net negative charge of the one or more nanoparticles causes the one or more nanoparticles to repel each other with a force of repulsion that leads to stable dispersion of the one or more nanoparticles when the first composition is diluted at least up to 10 fold with an aqueous fluid.

14 . The composition of claim 1 , wherein the one or more nanoparticles has a net positive charge that is +15 mV or higher.

15 . The composition of claim 14 , wherein the net positive charge is mainly generated by a plurality of emulsifying agents, associated with the one or more nanoparticles, selected from the group consisting of Ethyl lauroyl arginate, dialkyl ammonium chloride, monoalkyl ammonium chloride, chitosan, n-dodecyl dimethyl benzyl ammonium chloride, n-dodecyl dimethyl ethylbenzyl ammonium chloride, n-hexadecyl dimethyl benzyl ammonium chloride, n-octadecyl dimethyl benzyl ammonium chloride, n-tetradecyl dimethyl benzyl ammonium chloride, n-tetradecyl dimethyl ethylbenzyl ammonium chloride, and a combination thereof.

16 . The composition of claim 1 , wherein size, polydispersity, and force of repulsion of the one or more nanoparticles produce a bloom effect, wherein the bloom effect of the one or more nanoparticles prevents sublimation of ice crystals from a surface of a substrate, thereby preventing freezer burn of the composition.

17 . The composition of claim 1 , wherein the one or more nanoparticles are 0.01 wt % to 70 wt % of the composition.

18 . The composition of claim 1 , wherein the one or more nanoparticles further comprises a bioenhancer ingredient selected from the group consisting of aloin A, aloin B, emodin, 2-gingerol, 4-gingerol, 6-gingerol, 8-gingerol, 10-gingerol, 12-gingerol, 6-shogaol, 10-shogaol, 6-paradol, Niazirin, niaziridin, bergamottin, genistein, isoquercetin, isorhamnetin, kaempferol, naringin, naringinin, nobiletin, quercetin, quercitrin, tangeritin, rutin, tamarixetin 6′,7′-dihydroxybergamottin, resveratrol, trans-resveratro, cis-resveratrol, luteolin, luteolin-7-O-glucoside, stevioside, steviol, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, stigmasterol, stigmasterol-3-O-beta-d-glucoside, beta-sitosterol, caffeic acid, chicoric acid, cinnamic acid, chlorogenic acid, gallic acid, green tea, catechin, catechin gallate, epicatechin, epicatechin gallate, epigallocatechin, and epigallocatechin gallate, sodium and potassium salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, glycochenodeoxycholic acid, taurodeoxycholic acid, glycodeoxycholic acid, tauroursodeoxycholic acid, glycoursodeoxycholic, lithocholic acid, or combinations thereof.

19 . The composition of claim 1 , wherein the composition further comprises a bioenhancer ingredient selected from the group consisting of Allicin, Capsaicinoids, Homocapsaicin, dihydrocapsaicin, homodihydrocapsaicin, noredihydrocapsaicin, nonivamide, capsaicin, alkaloids, berberine, bidesmethoxycurcumin, curcumin, desmethoxycurcumin, lysergol, piperine, piperidine, sinomenine, terpenes, terpenoids, 1-8 cineole, bergamotene, carvacrol, carvone, caryophyllene, elemene, eugenol, farnesene, geraniol, glycyrrhizin, humulene, kaurene, limonene, pinene, sterebin A, sterebin B, sterebin C, sterebin D, sterebin E, sterebin F, sterebin G, sterebin H, terpinen-4-ol, gamma-terpinene, alpha-terpineol, terpinolene, kavalactones, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin, kavain, and dihydrokavain, alpha-boswellic acid, beta-boswellic acid, bile acid acids, cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, glycochenodeoxycholic acid, taurodeoxycholic acid, glycodeoxycholic acid, tauroursodeoxycholic acid, glycoursodeoxycholic, lithocholic acid, GRAS triglycerides, diglycerides, and monoglycerides, or combinations thereof.

20 . A composition for oral consumption, comprising:

an aqueous suspension, comprising:

a first plurality of active ingredients selected from the group consisting of methylphenidate, dextroamphetamine, amphetamine, dextroamphetamine, Caffeine, nicotine, Methamphetamine, 3,4-Methylenedioxymethamphetamine, Methylenedioxypyrovalerone, Mephedrone, Phenylpropanolamine, Propylhexedrine, Pseudoephedrine, Catha edulis , Modafinil, xanthine derivatives, theophylline, and theobromine, wherein:

the first plurality of active ingredients are soluble in the aqueous suspension; and

one or more nanoparticles, wherein:

the one or more nanoparticles encapsulate a second plurality of active ingredient selected from the group consisting of Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna , black truffle, Syzygium aromaticum, Rosmarinus oficinalis, Sceletium tortuosum , Holy basil, Oregano, Lavender, Cinnamon, Malabathrum, Cananga odorata, Ginkgo Biloba, Bacopa , and Rhodiola rosea , Ashwagandha, Astragalus, Chaga, Cordyceps , Corydalis, Curcumin, Damiana, Eleuthero, Ginger root, Ginseng , Gotu Kola, Lion's Mane, Maca, Passionflower, Saffron, Schisandra, St. John's Wort, Turmeric, Turkey Tail, Valerian root, and Yohimbe;

the one or more nanoparticles further comprises:

a plurality of emulsifying agents selected from the group consisting of an extract of Quillaja, extract of Licorice, polysorbate 20, polysorbate 40, polysorbate 45, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81 and polysorbate 85, polyglyceryl, gum acacia, Polyglycerol polyricinoleate, sorbitan 85, sorbitan 65, sorbitan 83, sorbitan 80, sorbitan 60, sorbitan 40, Xanthan gum, sorbitol, mannitol, glycerol, sodium alginate, lecithin, chemically modified lecithin, purified components of lecithin, phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, and cardiolipin, hydrogenated soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, tocopherol polyethylene glycol succinate, fatty acid mono-and di-glycerides, acetic acid esters of mono-and di-glycerides, lactic acid esters of mono-and di-glycerides, citric acid esters of mono-and di-glycerides, diacetyl tartaric acid ester of mono-and di-glycerides, triglycerol monooleate, hexaglycerol octasterate, polyglycerol esters of oleic acid, decaglycerol mono-and di-oleate, glyceryl caprylate, glyceryl caprate, glyceryl caprate/caprylate, glyceryl monooleate, glycerly monostearate, poloxamers, milk proteins, casein, pea proteins, whey proteins, collagen, sodium stearoyl lactylate, extract of bacopa, withaferin A, withaferin B, withanolide A, withanolide B, withanolide C, withanolide D, withanolide E, withanolide F, withanolide G, withanoside I, withanoside II, withanoside III, withanoside IV, withanoside V, withanoside VI, withanoside VII, bacopaside I, bacopaside II, bacopaside III, bacopaside IV, bacopaside V, bacopaside VI, bacopaside VII, bacopaside VIII, bacopaside IX, bacopaside X, bacopaside XI, bacopaside XII, bacopaside N1, bacopaside N2, bacosaponin A, bacosaponin B, bacosaponin C, bacosaponin D, bacosaponin E, bacosaponin F, bacosaponin G, bacosaponin H, bacoside A3, bacosine, or combinations thereof;

the one or more nanoparticles solubilize the second plurality of active ingredients in the aqueous suspension;

the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers;

the one or more nanoparticles has a net negative charge that is-15 mV or lower;

the one or more nanoparticles comprise a crosslinked hydrophilic polymer network at an interface of the one or more nanoparticles;

the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 40° C. for four weeks; and

the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 90° C. for 30 minutes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2022
From: MOASERI, EHSAN
To: NULIXIR INC.
Reel/Frame 061394/0710 →
Continuity (4)
Provisional Application 63356389 · Jun 28, 2022
Provisional Application 63321596 · Mar 18, 2022
Provisional Application 63244105 · Sep 14, 2021
Related Publication 20230111238A1 · Apr 13, 2023
References Cited (142)
US 5296224A · Schwabe · 1994 [cited by applicant]
US 5332595A · Gaonkar · 1994 [cited by applicant]
US 6720007B2 · Walt et al. · 2004 [cited by applicant]
US 10028919B2 · Kaufman · 2018 [cited by applicant]
US 10738268B2 · Leo · 2020 [cited by applicant]
US 10851077B2 · Durkacz et al. · 2020 [cited by applicant]
US 10945953B1 · Moaseri · 2021 [cited by applicant]
US 11497760B2 · Saar et al. · 2022 [cited by applicant]
US 11497809B2 · Wu et al. · 2022 [cited by applicant]
US 11964049B2 · Moaseri · 2024 [cited by examiner]
US 20020086438A1 · Elsohly et al. · 2002 [cited by applicant]
US 20050208134A1 · Magdassi et al. · 2005 [cited by applicant]
US 20060188534A1 · Muller · 2006 [cited by applicant]
US 20090186093A1 · Liu et al. · 2009 [cited by applicant]
US 20100068290A1 · Ziegler et al. · 2010 [cited by applicant]
US 20100193349A1 · Braam · 2010 [cited by applicant]
US 20100255087A1 · Coulter · 2010 [cited by applicant]
US 20110021592A1 · Magdassi et al. · 2011 [cited by applicant]
US 20110091636A1 · Elleman et al. · 2011 [cited by applicant]
US 20110111020A1 · Yan et al. · 2011 [cited by applicant]
US 20110182998A1 · Reb et al. · 2011 [cited by applicant]
US 20110189298A1 · Vos et al. · 2011 [cited by applicant]
US 20130316006A1 · Popov et al. · 2013 [cited by applicant]
US 20140037744A1 · Buisson et al. · 2014 [cited by applicant]
US 20140154191A1 · Doucet · 2014 [cited by applicant]
US 20150104545A1 · Dardelle et al. · 2015 [cited by applicant]
US 20150150822A1 · Perumal et al. · 2015 [cited by applicant]
US 20150158004A1 · Meiners et al. · 2015 [cited by applicant]
US 20150190348A1 · Haksar et al. · 2015 [cited by applicant]
US 20150209298A1 · Haksar et al. · 2015 [cited by applicant]
US 20160008237A1 · Goldstein et al. · 2016 [cited by applicant]
US 20170079921A1 · Krishnamurthy et al. · 2017 [cited by applicant]
US 20170157049A1 · Dandl et al. · 2017 [cited by applicant]
US 20170281558A1 · Castan et al. · 2017 [cited by applicant]
US 20170368022A1 · Sorbo et al. · 2017 [cited by applicant]
US 20180296493A1 · Kaufman · 2018 [cited by applicant]
US 20190105261A1 · Waugh et al. · 2019 [cited by applicant]
US 20190201350A1 · White et al. · 2019 [cited by applicant]
US 20190254302A1 · Abbaspourrad et al. · 2019 [cited by applicant]
US 20190358169A1 · Bishop et al. · 2019 [cited by applicant]
US 20200037638A1 · Faraci · 2020 [cited by examiner]
US 20200079751A1 · Durkacz et al. · 2020 [cited by applicant]
US 20210023155A1 · Opperman · 2021 [cited by applicant]
US 20210069083A1 · Meyer et al. · 2021 [cited by applicant]
US 20210169816A1 · Moaseri · 2021 [cited by applicant]
US 20210177754A1 · Keller et al. · 2021 [cited by applicant]
US 20220241305A1 · Erickson et al. · 2022 [cited by applicant]
US 20230079480A1 · Moaseri · 2023 [cited by applicant]
US 20230081296A1 · Moaseri · 2023 [cited by applicant]
US 20230082651A1 · Moaseri et al. · 2023 [cited by applicant]
US 20230110485A1 · Moaseri et al. · 2023 [cited by applicant]
US 20230111190A1 · Moaseri et al. · 2023 [cited by applicant]
US 20230111238A1 · Moaseri · 2023 [cited by applicant]
US 20230111756A1 · Moaseri et al. · 2023 [cited by applicant]
US 20230149829A1 · Moaseri · 2023 [cited by applicant]
US 20230157963A1 · Moaseri et al. · 2023 [cited by applicant]
US 20230157964A1 · Kvitnitsky et al. · 2023 [cited by applicant]
US 20230157973A1 · Moaseri et al. · 2023 [cited by applicant]
EP 2201937A1 · 2010 [cited by applicant]
WO 2010013224A2 · 2010 [cited by applicant]
WO 2018152334A1 · 2018 [cited by applicant]
WO 2018183115A1 · 2018 [cited by applicant]
WO 2019071213A1 · 2019 [cited by applicant]
WO 2019204630A1 · 2019 [cited by applicant]
WO 2020037403A1 · 2020 [cited by applicant]
WO 2020044116A1 · 2020 [cited by applicant]
WO WO2020104970A2 · 2020 [cited by examiner]
WO 2020186212A1 · 2020 [cited by applicant]
WO 2022157726A1 · 2022 [cited by applicant]
WO 2022201066A1 · 2022 [cited by applicant]
Kesarwani K, Gupta R, Mukerjee A. Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed. Apr. 2013;3(4):253-66. doi: 10.1016/S2221-1691(13)60060-X. PMID: 23620848; PMCID: PMC3634921. (Year: 20… [cited by examiner]
Kesarwani_Bioavailability_Enhancers (Year: 2013). [cited by examiner]
M. Logozzi, et al., “The Potentiality of Plant-Derived Nanovesicles in Human Health—A Comparison with Human Exosomes and Artificial Nanoparticles,” International Journal of Molecular Sciences, Apr. 28, 2022, https://www… [cited by applicant]
M. Logozzi, “Nanovesicles from Organic Agriculture—Derived Fruits and Vegetables: Characterization and Functional Antioxidant Content,” International Journal of Molecular Sciences, vol. 22, Issue 15, Jul. 29, 2021, http… [cited by applicant]
Extended Search Report for related European Patent Application 20862499.9 received Aug. 4, 2023, 15 pages. [cited by applicant]
Muschiolik, Gerald, et al., “Double Emulsions Relevant to Food Systems: Preparation, Stability, and Applications: Double emulsions in food,” Comprehensive Reviews in Food Science and Food Safety, Institute of food techn… [cited by applicant]
International Preliminary Report on Patentability for related International Patent Application PCT/US2022/043549 issued on Mar. 28, 2024, 5 pages. [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/945,038 issued May 22, 2024, 17 pages. [cited by applicant]
International Search Report and Written Opinion for related International Patent Application PCT/US2022/043549 issued on Jan. 16, 2023, 8 pages. [cited by applicant]
Peshkovsky, Alexey. “CAN CBD or THC Be Made Water-Soluble?” Can CBD or THC Be Made Water-Soluble?, Jul. 3, 2016, blog.sonomechanics.com/blog/water-soluble-cbd (Year: 2016). [cited by applicant]
Santamaria-Echart et al. “New Trends in Natural Emulsifiers and Emulsion Technology for the Food Industry” Natural Food Additives, Sep. 1, 2021, https://www.intechopen.com/chapters/78387 (Year: 2021). [cited by applicant]
Molaveisi, Mohammad, et al. “Controlled Release and Improved Stability of Vitamin D3 Within Nanoliposomes Stabilized by Palmitic Acid.” Journal of food safety 41.5 (2021 ): n. pag. Web (Year: 2021). [cited by applicant]
Non-Final Office Action issued in related U.S. Appl. No. 17/945,038, dated Aug. 11, 2023. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/945,037 issued on Jul. 30, 2024, 98 pages. [cited by applicant]
Dionisio, Marita, et al. “Locust bean gum: Exploring its potential for biopharmaceutical applications,” Journal of Pharmacy and Bioallied Sciences, 31 pages [online], 2012, [retrieved on Oct. 30, 2024]. Retrieved from t… [cited by applicant]
Pateiro, Mirian, et al. “Nanoencapsulation of Promising Bioactive Compounds to Improve Their Absorption, Stability, Functionality and the Appearance of the Final Food Products,” molecules, 26 pages [online], 2021 [retri… [cited by applicant]
Biswas, Sayan, et al. “Optimized piperine-phospholipid complex with enhanced bioavailability and hepatoprotective activity,” Pharmaceutical Development and Technology, 6 pages [online], 2021, [retrieved on Oct. 30, 2024… [cited by applicant]
“Ashwagandha and Rhodiola—Combination,” 8 pages [online], 2015 [retrieved on Oct. 30, 2024]. Retrieved from the Internet: <URL: https://88herbs.com/ashwagandha-rhodiola-combination/>. [cited by applicant]
Napierała, Marta, et al. “Nicotine and caffeine: influence on dopaminergic transmission,” abstract, 1 page [online], 2016 [retrieved on Oct. 30, 2024]. Retrieved from the Internet: <URL: https://pubmed.ncbi.nlm.nih.gov/… [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/945,035, issued on Jan. 7, 2025, 40 pages. [cited by applicant]
Sungpud, C., et al., Ultrasonic-assisted virgin coconut oil based extraction for maximizing polyphenol recovery and bioactivities of mangosteen peels, 2020, J Food Sci Technol., 57( 11 ):4032-4043, 12 pages. <https://do… [cited by applicant]
Wu, J., et al., Ultrasound-assisted extraction of ginseng saponins from ginseng roots and cultured ginseng cells, 2001, Ultrasonics Sonochemistry, 8:347-352, 6 pages. <https://doi.org/10.1016/S1350-4177(01)00066-9> (Yea… [cited by applicant]
Da Silva, S. B., et al., Chitosan-based nanoparticles for rosmarinic acid oculardelivery-In vitro tests, 2016, Int J Bio Macromolecules, 84:112-120, 9 pages. <dx.doi.org/10.1016/j.ijbiomac.2015.11.070> (Year: 2016). [cited by applicant]
Jafarinejad, S., 7—Solid-Waste Management in the Petroleum Industry, 2017, Petroleum Waste Treatment and Pollution Control, pp. 269-345, 7 pages. <https://doi.org/10.1016/B978-0-12-809243-9.00007-9> (Year: 2017). [cited by applicant]
Majors, R.E., Salting-out liquid-liquid extraction (SALLE), 2009, Chromatography Online, 13 pages. Accessed Dec. 11, 2024. < https://www.chromatographyonline.com/view/salting-out-liquid-liquid-extraction-salle> (Year: 2… [cited by applicant]
Singh, T., et al., Application of Nanotechnology in Food Science: Perception and Overview, 2017, Frontiers Microbial., 8:1501, 7 pages. <https://doi.org/10.3389/fmicb.2017.01501> (Year: 2017). [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/945,038, issued on Feb. 12, 2025, 40 pages. [cited by applicant]
Nushtaeva, “Natural food-grade solid particles for emulsion stabilization”, Colloids and Surfaces A: Physicochem. Eng. Aspects, 2016, 504, 449-457. (Year: 2016). [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/945,011, issued on Feb. 12, 2025, 79 pages. [cited by applicant]
Luque de Castro, M.D. and Garcia-Ayuso, L.E .. Soxhlet extraction of solid materials: an outdated technique with a promising innovative future. Analytica Chimica Acta, 369, p. 1-10. (Year: 1998). [cited by applicant]
Elgie, K.. What is a Rotary Evaporator ?. httos:/Awww.asynt.com/blog/what-is-a-rotary-evaporator/, posted Feb. 14, 2022 (Year: 2022). [cited by applicant]
Chemat, F., Rombaout, N., Sicaire, A-G., Meullemiestre, A., Fabiano-Tixier, A-S., and Abert-Vian, M.. Ultrasound assisted extraction of food and natural products. Mechanisms, techniques, combinations, protocols and appl… [cited by applicant]
Majekodunmi, S.O.. Review of extraction of medicinal plants for pharmaceutical research. Merit Research Journal of Medicine and Medicinal Sciences, 3, p. 521-527. (Year: 2015). [cited by applicant]
Prausnitz, P. H.. Fritted Glass Filter Disks. Industrial and Engineering Chemistry, 16, p. 370. (Year: 1924). [cited by applicant]
Chinapongtitiwat, V., Jongaroontaprangsee, S., Chiewchan, N., Devahastin, S.. Important flavonoids and limonin in selected Thai citrus residues. Journal of Functional Foods, 5, p. 1151-1158. (Year: 2013). [cited by applicant]
Smith, M.C., Crist, R.M., Clogston, J.D., and McNeil, S.E.. Zeta potential: a case study of cationic, anionic, and neutral liposomes. Anal Bioanal Chem, 409, p. 5779-5787. (Year: 2017). [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/945,037, issued on Mar. 19, 2025, 27 pages. [cited by applicant]
“Stomach Acid Test.” Mount Sinai Health System, https://web.archive.org/web/20170203235855/https://www.mountsinai.org/health-library/tests/stomach-acid-test. Retrieved Jan. 10, 2024. (Year: 2017). [cited by applicant]
Melro, Elodie et al. “Chitosan Films in Food Applications. Tuning Film Properties by Changing Acidic Dissolution Conditions.” Polymers vol. 13,1 1. Dec. 22, 2020, doi:10.3390/polym13010001 (Year: 2020). [cited by applicant]
Non-Final Office Action issued for corresponding U.S. Appl. No. 17/944,985, dated Jan. 19, 2024. [cited by applicant]
Final Office Action issued for corresponding U.S. Appl. No. 17/944,985, dated Oct. 28, 2024. [cited by applicant]
Pall, Introduction to Tangential Flow Filtration for Laboratory and Process Development Applications, Published 2003 (Year: 2003). [cited by applicant]
Non-Final Office Action issued for corresponding U.S. Appl. No. 17/945,036, dated Sep. 25, 2024. [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/945,036, issued on Jun. 12, 2025, 31 pages. [cited by applicant]
Non-Final Office Action for related U.S. Patent Application 17/944,985, issued on Jun. 17, 2025, 17 pages. [cited by applicant]
Non-Final Office Action for related U.S. Appl. No. 17/945,012, issued on Jul. 1, 2025, 140 pages. [cited by applicant]
Final Office Action for related U.S. Appl. No. 17/945,035, issued on Jul. 28, 2025, 36 pages. [cited by applicant]
Final Rejection issued for Related U.S. Appl. No. 17/945,011, dated Sep. 23, 2025; 33 pages. [cited by applicant]
Non-Final Office Action Issued in Related U.S. Appl. No. 17/945,037, dated Oct. 1, 2025; 14 pages. [cited by applicant]
Final Rejection Issued in Related U.S. Appl. No. 17/945,038, dated Nov. 13, 2025; 26 pages. [cited by applicant]
Non-Final Office Action Issued in Related U.S. Appl. No. 17/945,036, dated Feb. 5, 2026; 13 pages. [cited by applicant]
Non-Final Office Action Issued in Related U.S. Appl. No. 17/945,001, dated Jan. 26, 2026, 21 pages. [cited by applicant]
Szukalska, et al. (Nicotine and Caffeine: Influence on Dopaminergic Transmission, 2016). Year: 2016. [cited by applicant]
Ovadia, et al. (Journal of Pharmaceutical Sciences, 1965, vol. 54, pp. 1013-1016) Year: 1965. [cited by applicant]
Stearic Acid SDS obtained from ThermoFisher (Jun. 2, 2014), pp. 1-8 (Year: 2014). [cited by applicant]
Krave Beauty, “Should I Refrigerate My Skincare?”, 2019, pp. 1-3 (Year: 2019). [cited by applicant]
https://88herbs.com/ashwagandha-rhodiola-combination/ (Year: 2015). [cited by applicant]
Final Office Action Issued in U.S. Appl. No. 17/945,012, dated Mar. 19, 2026, 25 pages. [cited by applicant]
Non-Final Office Action Issued in U.S. Appl. No. 17/945,011, dated Apr. 21, 2026, 26 pages. [cited by applicant]
Non-Final Office Action Issued in U.S. Appl. No. 17/945,038, dated May 6, 2026, 33 pages. [cited by applicant]
Final Office Action Issued in U.S. Appl. No. 17/945,037, dated May 13, 2026, 14 pages. [cited by applicant]
Final Office Action Issued in U.S. Appl. No. 18/168,394, dated May 18, 2026, 126 pages. [cited by applicant]
Kesarwani, “Bioavailability Enhancers of Herbal Origin: An Overview,” Asian Pacific Journal of Tropical Biomedicine, 3 (4): pp. 253-266, 2013. [cited by applicant]
Dionisio, et al. “Locust Bean Gum: Exploring Its Potential for Biopharmaceutical Applications,” J. Pharm Bioallied Sci, 2012. [cited by applicant]
Biswas, et al., “Optimized Piperine-Phospholipid Complex with Enhanced Bioavailability and Hepatoprotective Activity,” Pharmaceutical Development and Technology, 2021. [cited by applicant]
Pateiro, et al., Nanoencapsulation of Promising Bioactive Compounds to Improve Their Absorption, Stability, Functionality, and the Apperance of the Final Food Products; Molecules, 2021. [cited by applicant]
Abbaspoor, Sogand, Ali Ashrafi, and Mehdi Salehi, “Synthesis and Characterization of Ethyl Celullose Micro/ Nanocapsules Using Solvent Evaporation Method,” Colloid and Polymer Science 296.9 (2018): 1509-1514. [cited by applicant]
Tepsongkroh, Benjarat, et al., “Influence of Polyglycerol Polyricinoleate and Biopolymers on Physical Properties and Encapsulation Efficiency of Water-In-Oil-In-Water Emulsions Containing Mango Seed Kernel Extract,” Jou… [cited by applicant]
Vergallo, Cristian, “Nutraceutical Vegetable Oil Nanoformulations for Prevention and Management of Diseases,” Nanomaterials 10.6 (2020): 1232. [cited by applicant]
Fundueanu, Gheorghe, et al., “Preparation and Characterization of Ca-alginate Microspheres by a New Emulsification Method,” International Journal of Pharmaceutics 170.1 (1998): 11-21. [cited by applicant]
Zidan, Ahmed, Osama AA Ahmed, and Bader M. Ajaeid, “Nicotinamide Polymeric Nanoemulsified Systems: A Quality-By-Design Case Study for a Sustained Antimicrobial Activity,” International Journal of Nanomedicine (2016): 15… [cited by applicant]
Mu, Li and Shi-Shen Feng, “Vitamin E-TPGS Used as Emulsifier in the Solvent Evaporation/Extraction Technique for Fabrication of Polymeric Nanospheres for Controlled Release Paclitaxel (TaxolA),” Journal of Controlled Re… [cited by applicant]